Compare Johnson & Johnson (JNJ) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs VNET Group Inc — how do they compare? Johnson & Johnson trades at $256.5 (market cap $618.09B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: Johnson & Johnson is far larger — about 420.5× VNET Group Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and VNET Group Inc for 16 Days on average.
| JNJ | VNET | |
|---|---|---|
Market Cap | $618.09B | $1.47B |
Volume | 6,050,983 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $278.43 | $14.03 |
52-Week Low | $186.00 | $5.13 |
Typical Hold Time | 129 Days | 16 Days |
Enterprise Value | $646.37B | $5.04B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
VNET trades at $5.42, up 0.56% today but near a 52-week low. Technicals are bearish with moving averages signaling sell, while fundamentals show revenue growth to $9.95B in 2025 but net losses of $256.77M. Recent news includes a strategic investment closing and a new low, reflecting mixed sentiment amid high institutional interest and negative cash flow trends.
Outlook: Strategic partnerships and AI demand offer growth, but high debt, negative margins, and bearish technicals pose significant risks. Analyst consensus is moderately bullish (62.5% buy), yet profitability challenges and leverage require caution for investors seeking turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
